scholarly journals A Neglected Drama for Elders: Discrepancy Between Self-Perception and Objective Performance Regarding Financial Capacity in Patients With Cognitive Deficits

2015 ◽  
Vol 8 (2) ◽  
pp. 142-147 ◽  
Author(s):  
Vaitsa Giannouli ◽  
Magda Tsolaki

The article aims at investigating whether patients from Greece with different kinds of cognitive deficits (resulting from Alzheimer’s Disease, Parkinson’s Disease Dementia, and Mild Cognitive Impairment) can be characterized as financially capable (based on neuropsychological assessment), and if this claimed (in)capacity is in accordance with their personal belief of (in)capacity. Results revealed that the vast majority of the mild, moderate and severe Alzheimer’s disease patients as well as patients with Mild Cognitive Impairment and Parkinson’s disease, who scored significantly lower than normal on a relevant financial decision-making capacity test, believed that they were capable to handle their finances. This finding is in contrast with their actual financial capacity scores and the beliefs of their family members-caregivers on this issue. Some critical questions concerning incapacity and intellectual insight are raised, and future cross-cultural investigative attempts on this issue are suggested.

2019 ◽  
Vol 34 (8) ◽  
pp. 1244-1250 ◽  
Author(s):  
Eleanor King ◽  
John O'Brien ◽  
Paul Donaghy ◽  
Caroline H. Williams-Gray ◽  
Rachael A. Lawson ◽  
...  

2017 ◽  
Vol 13 (7S_Part_8) ◽  
pp. P416-P416
Author(s):  
Ting Ting Yong ◽  
Russell J. Chander ◽  
Heidi Emmanuel Foo ◽  
Levinia Lim ◽  
Aloysius Yue Tat Ng ◽  
...  

BMC Neurology ◽  
2006 ◽  
Vol 6 (1) ◽  
Author(s):  
Rita J Guerreiro ◽  
Jose M Bras ◽  
Isabel Santana ◽  
Cristina Januario ◽  
Beatriz Santiago ◽  
...  

2015 ◽  
Vol 29 (3) ◽  
pp. 112-119 ◽  
Author(s):  
Johann Lehrner ◽  
Harald Krakhofer ◽  
Claus Lamm ◽  
Stefan Macher ◽  
Doris Moser ◽  
...  

2018 ◽  
Vol 265 (6) ◽  
pp. 1365-1375 ◽  
Author(s):  
David R. Roalf ◽  
Petra Rupert ◽  
Dawn Mechanic-Hamilton ◽  
Laura Brennan ◽  
John E. Duda ◽  
...  

2019 ◽  
Vol 20 (18) ◽  
pp. 4432 ◽  
Author(s):  
Jeannie Hwang ◽  
Candice M. Estick ◽  
Uzoma S. Ikonne ◽  
David Butler ◽  
Morgan C. Pait ◽  
...  

Many neurodegenerative disorders have lysosomal impediments, and the list of proposed treatments targeting lysosomes is growing. We investigated the role of lysosomes in Alzheimer’s disease (AD) and other age-related disorders, as well as in a strategy to compensate for lysosomal disturbances. Comprehensive immunostaining was used to analyze brains from wild-type mice vs. amyloid precursor protein/presenilin-1 (APP/PS1) mice that express mutant proteins linked to familial AD. Also, lysosomal modulation was evaluated for inducing synaptic and behavioral improvements in transgenic models of AD and Parkinson’s disease, and in models of mild cognitive impairment (MCI). Amyloid plaques were surrounded by swollen organelles positive for the lysosome-associated membrane protein 1 (LAMP1) in the APP/PS1 cortex and hippocampus, regions with robust synaptic deterioration. Within neurons, lysosomes contain the amyloid β 42 (Aβ42) degradation product Aβ38, and this indicator of Aβ42 detoxification was augmented by Z-Phe-Ala-diazomethylketone (PADK; also known as ZFAD) as it enhanced the lysosomal hydrolase cathepsin B (CatB). PADK promoted Aβ42 colocalization with CatB in lysosomes that formed clusters in neurons, while reducing Aβ deposits as well. PADK also reduced amyloidogenic peptides and α-synuclein in correspondence with restored synaptic markers, and both synaptic and cognitive measures were improved in the APP/PS1 and MCI models. These findings indicate that lysosomal perturbation contributes to synaptic and cognitive decay, whereas safely enhancing protein clearance through modulated CatB ameliorates the compromised synapses and cognition, thus supporting early CatB upregulation as a disease-modifying therapy that may also slow the MCI to dementia continuum.


2016 ◽  
Vol 27 ◽  
pp. 54-60 ◽  
Author(s):  
Lilah M. Besser ◽  
Irene Litvan ◽  
Sarah E. Monsell ◽  
Charles Mock ◽  
Sandra Weintraub ◽  
...  

2018 ◽  
Vol 76 (3) ◽  
pp. 145-149
Author(s):  
Carlos Henrique Ferreira Camargo ◽  
Augusto Bronzini ◽  
Eduardo de Souza Tolentino ◽  
Camila Medyk ◽  
Gustavo Leopold Schultz-Pereira

ABSTRACT The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery was created to assess cognitive impairment in Alzheimer's disease (AD) but it is widely-used for various dementias. The aim of this study was to analyze the efficacy of using the CERAD battery in the assessment of patients with Parkinson's disease. Forty-nine patients with Parkinson's disease were divided into two groups (one with dementia and one without) using the Movement Disorder Society criteria for Parkinson's disease dementia. Cognitive deficits were assessed with the Clinical Dementia Rating Scale as the gold standard, and the CERAD. The ROC curve for the CERAD battery had an area under the curve = 0.989 (95% CI = 0.967 – 1, p<0.0001). Among the CERAD subtests, verbal fluency had the worst accuracy, and word list learning had the best accuracy. Despite the limits of this study, the CERAD battery can be efficient for assessment of cognitive deficits in Parkinson's disease patients.


Sign in / Sign up

Export Citation Format

Share Document